NASDAQ:CRGX CARGO Therapeutics (CRGX) Stock Price, News & Analysis $4.49 +0.02 (+0.45%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.44 -0.04 (-1.00%) As of 08/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About CARGO Therapeutics Stock (NASDAQ:CRGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CARGO Therapeutics alerts:Sign Up Key Stats Today's Range$4.45▼$4.5050-Day Range$4.10▼$4.7552-Week Range$3.00▼$25.45Volume673,476 shsAverage Volume3.18 million shsMarket Capitalization$207.03 millionP/E RatioN/ADividend YieldN/APrice Target$15.40Consensus RatingReduce Company Overview CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California. Read More CARGO Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCRGX MarketRank™: CARGO Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 664th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingCARGO Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageCARGO Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about CARGO Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CARGO Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CARGO Therapeutics is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCARGO Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about CARGO Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CRGX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCARGO Therapeutics does not currently pay a dividend.Dividend GrowthCARGO Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CRGX. News and Social Media2.8 / 5News Sentiment1.08 News SentimentCARGO Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CARGO Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added CARGO Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CARGO Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of CARGO Therapeutics is held by insiders.Percentage Held by Institutions93.16% of the stock of CARGO Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CARGO Therapeutics' insider trading history. Receive CRGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CARGO Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRGX Stock News HeadlinesJefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold RatingJuly 29, 2025 | msn.comCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGXJuly 25, 2025 | businesswire.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZBJuly 25, 2025 | prnewswire.comCRGX - Cargo Therapeutics Inc Financials | MorningstarJuly 19, 2025 | morningstar.comMCARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...July 11, 2025 | morningstar.comMCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Seeking AlphaJuly 9, 2025 | seekingalpha.comCARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - MorningstarJuly 9, 2025 | morningstar.comMSee More Headlines CRGX Stock Analysis - Frequently Asked Questions How have CRGX shares performed this year? CARGO Therapeutics' stock was trading at $14.42 at the start of the year. Since then, CRGX stock has decreased by 68.9% and is now trading at $4.49. How were CARGO Therapeutics' earnings last quarter? CARGO Therapeutics, Inc. (NASDAQ:CRGX) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.88) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.26. When did CARGO Therapeutics IPO? CARGO Therapeutics (CRGX) raised $281 million in an initial public offering (IPO) on Friday, November 10th 2023. The company issued 18,750,000 shares at a price of $15.00 per share. Who are CARGO Therapeutics' major shareholders? Top institutional investors of CARGO Therapeutics include Public Employees Retirement System of Ohio (0.05%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Perceptive Advisors Llc, Gina Chapman and Anup Radhakrishnan. View institutional ownership trends. How do I buy shares of CARGO Therapeutics? Shares of CRGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CARGO Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CARGO Therapeutics investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/12/2024Today8/02/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRGX Previous SymbolNASDAQ:CRGX CIK1966494 Webcargo-tx.com Phone650-379-6143FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Price Target for CARGO Therapeutics$15.40 High Price Target$33.00 Low Price Target$4.00 Potential Upside/Downside+243.0%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($4.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$167.50 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.93% Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.83 per share Price / Book0.57Miscellaneous Outstanding Shares46,110,000Free Float44,764,000Market Cap$207.03 million OptionableN/A Beta0.28 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CRGX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CARGO Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CARGO Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.